Ildong to conduct clinical trials to develop IMDs

Ildong Pharmaceutical Co. has unveiled its plan to develop seven incrementally modified drugs (IMDs) this year, while undertaking the clinical trials of Cotromvix (clopidogrel + asprin), a dual-purpose drug to treat two different conditions.

With less content of aspirin (81 mg), Cotromvix is expected to improve patient’s compliance and lower adverse events such as hemorrhage. The drug will l...